Mohan Uttarwar, CEO
Humanity’s battle against terminal illnesses has been a long one in terms of research and treatment thus far. However, even with today’s sophisticated and evolving technologies, researchers find it difficult to consolidate data and collaborate effectively with partners and hospitals scattered across the globe. Leveraging the power of modern-day data engineering, iNDX Technologies is founded for the sole purpose of finding a cure for diseases like cancer and focuses on bolstering immune-oncology (I-O) research in the U.S. “Our motivation and inspiration is to help researchers and patients find a cure for cancer through technology,” says Mohan Uttarwar, CEO of iNDX Technology.
Focusing on academia and pharmaceutical companies in translational research, Uttarwar offers iCore: a cloud-based, mobile-enabled, informatics and analytics platform for I-O. “The industry is at a very interesting tipping point,” he says. “With the advent of immuno cancer therapy, oncology research is going through a paradigm shift, and the convergence of innovation in science, technology, and business models will transform the field in the near future.” Immuno cancer therapy bypasses the side effects that patients face as they undergo chemotherapy. While traditional cancer treatments are administered externally, I-O focuses on training the body to fight the disease internally, at a cellular level. “This was a fundamental breakthrough in biology and in understanding the immune system. Subsequently, we also witnessed major computational technology breakthroughs and implemented those in our solutions,” states Uttarwar.
iNDX Technology’s iCore platform leverages machine learning (ML), natural language processing (NLP), and cloud computing to help researchers consolidate and organize the massive amount of structured and unstructured data in the field.
Varying from genomic data and imaging to electronic health records (EHR) and clinical data, iCore aggregates the information from disparate, disconnected data silos for researchers to promptly access and utilize. “As much as it is a health issue, cancer is also a data problem,” explains Uttarwar. “iCore centralizes relevant information and creates what we call a single study view for researchers to examine.” The platform then analyzes and visualizes the data sets to streamline the subsequent process of interrogation, where researchers can conduct quick and accurate studies. “As a translational researcher, getting the right information at their fingertips— with minimal time delay—greatly affects the critical decision-making processes and fosters progress,” says Uttarwar.
With the advent of immuno cancer therapy, oncology research is going through a paradigm shift, and the convergence of innovation in science, technology, and business models will transform the field in the near future
Team iNDX understands the criticality of collaboration and its advantages in the field of cancer research and has, therefore, designed its platform to support collaboration over multiple devices and systems across various institutions. For instance, iNDX’s iCore platform empowered PICI Console for researchers at the Parker Institute for Cancer Immunotherapy (PICI) and its collaborators such as Stanford, UCSF, UCLA, Sloan Kettering, UPENN and MD Anderson (with Nobel Prize winner, Dr. Jim Alison). The iCore platform empowered the study teams to monitor the patients’ health in clinical trials from a sample-centric perspective across the broad ecosystem of laboratories, sites, and biobanks. With the vision to continually bolster cancer research, the company is prepared to support all collaborative efforts for the same. “We, as a team of physicians, scientists, engineers, and entrepreneurs, with over 100 years of combined experience, transitioned from diagnostic to translational research to focus completely on helping researchers find a cure for cancer.” Having aided researchers in academia as well as industry, iNDX Technology is dedicated to delving deeper into the realm of biology and technology to find the perfect intersection between the two.